Literature DB >> 8695842

The proto-oncogene c-myc blocks myeloid differentiation independently of its target gene ornithine decarboxylase.

M Selvakumaran1, D Liebermann, B Hoffman.   

Abstract

Ornithine decarboxylase (ODC), a rate-limiting enzyme of polyamine biosynthesis, has been shown to be required for entry into and progression through the cell cycle and to be a transcriptional target of the proto-oncogene, c-myc. We show that ODC transcripts and enzyme activity are down-regulated following induction of myeloid differentiation, using M1 myeloblastic leukemic cells and normal cells from bone marrow (BM), and fail to be suppressed when c-myc expression is deregulated. In M1mycer cells, when endogenous c-myc expression has been suppressed following stimulation by interleukin-6 (IL-60), treatment with estrogen and cycloheximide results in induction of ODC transcripts. These data demonstrate that ODC is a c-myc target gene in M1 cells. It was of interest to determine whether deregulated ODC expression would alter the myeloid differentiation program. To answer this question, M1-ODC cell lines constitutively expressing ODC were established. These cells can undergo terminal differentiation and growth arrest following IL-6 stimulation, exactly like parental M1 cells, demonstrating that deregulated ODC expression is not sufficient to block myeloid differentiation. Another question to be answered was whether ODC expression is necessary for the c-myc-mediated block in differentiation. The use of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC enzyme activity, indicates that ODC is not necessary for the c-myc-mediated differentiation block.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695842

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.

Authors:  Lan Wang; Guang-Biao Zhou; Ping Liu; Jun-Hong Song; Yang Liang; Xiao-Jing Yan; Fang Xu; Bing-Shun Wang; Jian-Hua Mao; Zhi-Xiang Shen; Sai-Juan Chen; Zhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-14       Impact factor: 11.205

2.  Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.

Authors:  Zhifu Xiang; Hui Luo; Jacqueline E Payton; Jennifer Cain; Timothy J Ley; Joseph T Opferman; Michael H Tomasson
Journal:  J Clin Invest       Date:  2010-05-17       Impact factor: 14.808

3.  Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism.

Authors:  Franck Patin; Thomas Baranek; Patrick Vourc'h; Lydie Nadal-Desbarats; Jean-François Goossens; Sylviane Marouillat; Anne-Frédérique Dessein; Amandine Descat; Blandine Madji Hounoum; Clément Bruno; Hervé Watier; Mustafa Si-Tahar; Samuel Leman; Jean-Claude Lecron; Christian R Andres; Philippe Corcia; Hélène Blasco
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

4.  Redox-regulation of Erk1/2-directed phosphatase by reactive oxygen species: role in signaling TPA-induced growth arrest in ML-1 cells.

Authors:  Kassim Traore; Rajni Sharma; Rajesh K Thimmulappa; Walter H Watson; Shyam Biswal; Michael A Trush
Journal:  J Cell Physiol       Date:  2008-07       Impact factor: 6.384

5.  The metabolic regulator mTORC1 controls terminal myeloid differentiation.

Authors:  Pui Y Lee; David B Sykes; Sarah Ameri; Demetrios Kalaitzidis; Julia F Charles; Nathan Nelson-Maney; Kevin Wei; Pierre Cunin; Allyn Morris; Astrid E Cardona; David E Root; David T Scadden; Peter A Nigrovic
Journal:  Sci Immunol       Date:  2017-05-26

6.  Induction and Prevention of Gastric Cancer with Combined Helicobacter Pylori and Capsaicin Administration and DFMO Treatment, Respectively.

Authors:  Faisal Aziz; Mingxia Xin; Yunfeng Gao; Abhijit Chakroborty; Imran Khan; Josh Monts; Kjersten Monson; Ann M Bode; Zigang Dong
Journal:  Cancers (Basel)       Date:  2020-03-28       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.